<DOC>
	<DOCNO>NCT00308685</DOCNO>
	<brief_summary>This study design evaluate repeat-dose safety effectiveness bronchodilator inhaler relative placebo ( inactive drug inhaler ) child age 4-11 year asthma . The dosing period last three week start follow three-week run-in period .</brief_summary>
	<brief_title>Chronic-dose Safety Efficacy Study Bronchodilator Inhaler Pediatric Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Albuterol</mesh_term>
	<criteria>Persistent asthma minimum six month duration stable least four week prior screen Male female child age 411 year , inclusive , predict forced expiratory volume 1 second ( FEV1 ) 6090 % Ability perform spirometry Demonstrate 12 % airways reversibility Require continuous treatment betablockers , monoamine oxidase inhibitor , tricyclic antidepressant , anticholinergic , and/or systemic corticosteroid Presence nonasthmatic clinicallysignificant acute uncontrolled chronic disease</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Pediatric asthma</keyword>
</DOC>